-
Product Insights
Myxoid Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Myxoid Liposarcoma - Drugs In Development, 2023’, provides an overview of the Myxoid Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myxoid Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LB-100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Nerve Sheath Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Nerve Sheath Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Nerve Sheath Tumor Drug Details: LB-100 is under...
-
Product Insights
Pleomorphic Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleomorphic Liposarcoma - Drugs In Development, 2023’, provides an overview of the Pleomorphic Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleomorphic Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Leiomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Leiomyosarcoma - Drugs In Development, 2023’, provides an overview of the Leiomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Synovial Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Synovial Sarcoma - Drugs In Development, 2023’, provides an overview of the Synovial Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Liposarcoma - Drugs In Development, 2023’, provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WTX-330 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. WTX-330 in Solid Tumor Drug Details: WTX-330 is under development for the treatment of relapsed...